Patent · US Active

1,2-disubstituted heterocyclic compounds

US8933074B2 · kind B2 · utility

0Cited by

2References

16Claims

0Family size

Assignee

Forum Pharmaceuticals, Inc. · US

Inventors

Amy Ripka · Reading, US
Gideon Shapiro · Gainesville, US
Richard Chesworth · Boston, US

Key dates

Filing date	Jun 17, 2013
Grant date	Jan 13, 2015
Priority date	—
Expiry date	Jun 17, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.